STUDY QUESTION: Does exposure to menopausal hormone therapy (MHT) in mid-aged women alter their risk of cardiovascular disease (CVD) mortality and all-cause mortality?
Introduction
Considerable and on-going debate has occurred about the balance of benefits and risks of menopausal hormone therapy (MHT), notably with respect to the risk of chronic diseases, such as cardiovascular disease (CVD), and whether this balance changes according to the age of women when treatment starts or the timing relative to their menopausal status. There are two broad types of MHT, combined oestrogen and progestogen (progesterone) for women with an intact uterus and usually just oestrogen for women with prior hysterectomy. For women with a uterus, the combination of oestrogen and progestogen reduces the risk of endometrial cancer compared with oestrogen alone, but may cause adverse effects to blood lipid profiles (Boardman et al., 2015) .
Previous longitudinal studies have suggested that MHT may prevent CVD (Grodstein et al., 1999 (Grodstein et al., , 2000 . In 2002, however, the oestrogen plus progestogen component of the Women's Health Initiative (WHI) trial was stopped early due to evidence of increased risk of breast cancer for the treatment group compared with untreated women as well as other adverse effects of treatment outweighing benefits ( Writing Group for the Women's Health Initiative Investigators, 2002) . Furthermore, in 2004 the WHI Oestrogen-Alone trial for women with prior hysterectomy was halted early due to an increased risk of stroke and futility in terms of a favourable balance of benefit to risk in treated women (Anderson et al., 2004) . These unexpected results led to decreased use of MHT (Zbuk and Anand, 2012 ). An update of the WHI OestrogenAlone trial published in 2011 presented a subgroup analysis where women aged 50-59 showed evidence of a protective effect in terms of CVD, myocardial infarction and all-cause mortality (LaCroix et al., 2011) . A further update of both trials in 2013 (Manson et al., 2013) showed that women with an intact uterus taking the combined oestrogen and progestogen MHT were at increased risk for a range of adverse outcomes during treatment, although most risks and benefits dissipated when treatment stopped, except the breast cancer risk. Overall they found a complex pattern of risks and benefits, and while appropriate for management of symptoms among some women, there was insufficient evidence to support its use for chronic disease prevention. A 2015 update of a Cochrane review of 19 randomized studies of oral hormone therapy (either oestrogen alone or in combination with a progestogen) with over 40 000 women found no evidence overall of protective effects for all-cause mortality and a number of cardiovascular outcomes, but an increased risk of stroke and venous thromboembolism. Again, in a subgroup analysis, participants who started MHT within 10 years of experiencing menopause had lower mortality and coronary heart disease compared with untreated participants (Boardman et al., 2015) .
Given the uncertainty of benefits and risks of exposure to MHT in mid-aged women, we have investigated the relationship between exposure to MHT and risk of cardiovascular and all-cause mortality in a large longitudinal study of Australian women born 1946-1951, and further investigated whether these associations differed by menopausal status at initiation of treatment (i.e. peri, post and hysterectomy/ oophorectomy)? Because observational studies are known to be at higher risk of bias than randomized studies, and because of the previous inconsistent results reported for randomized trials compared with observational studies of MHT, we based our method of analysis on that used by Hernán et al. (2008) , who analysed an observational study of MHT like a randomized experiment and obtained consistent findings with those from the oestrogen plus progestogen WHI trial. Furthermore, we focussed on mortality as an objective measure of the overall impact of a medical intervention.
Materials and Methods

Participants
This population-based study uses data from the Australian Longitudinal Study on Women's Health (ALSWH), which assesses a broad range of lifestyle factors, as well as physical and mental health of Australian women. Three cohorts of different ages, a younger cohort (born 1978-1983) , a mid-aged cohort (born 1946-1951) and an older cohort (born 1921-1926) , have been followed since 1996. The present study focused on the 1946-1951 cohort, which was surveyed in 1996 (Wave 1, n = 13 715), 1998 (Wave 2, n = 12 338), 2001 (Wave 3, n = 11 226), 2004 (Wave 4, n = 10 905), 2007 (Wave 5, n = 10 638) and 2010 (Wave 6, n = 10 011). The study has been approved by Ethics Committees at the University of Queensland and University of Newcastle. Further information on ALSWH can be found in Dobson et al. (2015) .
Variables
At each survey for the 1946-1951 cohort, the women were asked if they were currently taking MHT and the answers were coded as 'yes' or 'no' or 'missing'. In addition, drug exposure information was available from mid-2002 to mid-2013 through linkage to the Australian Pharmaceutical Benefits Scheme (PBS) (2016). We used this information to determine the distribution of type of MHT prescribed to this cohort of women. The relationship between MHT and CVD mortality, as well as the association between MHT and overall mortality, was investigated after adjusting for baseline covariates and possible time-dependent confounders. Covariates considered for inclusion included those used by Hernán et al. (2008) that were also collected in the present study. The covariates included in the present study were age, SF36 physical function, relationship status, smoking status, self-rated health, mental health, level of education, BMI, exercise status, diabetes, heart disease, hypertension, stroke, osteoporosis and cancer. Mortality information including date and cause of death was obtained via linkage to the National Death Index (NDI) (2016).
Menopause status
Menopause status was determined based on answers to survey questions about hysterectomy, bilateral oophorectomy, hormone therapy, oral contraceptive pill (OCP) and menstrual pattern. Women who reported having a hysterectomy, bilateral oophorectomy or both, were classified as 'hysterectomy/oophorectomy'. Women who reported use of OCP, before reaching menopause or were unclassifiable (due to missing information) were denoted as 'other'. According to the definition of Guthrie et al. (1999) , women were defined as pre-menopausal if they had menstruated in the last 3 months and reported no change in menstrual frequency in the last 12 months; perimenopausal if they reported changes in menstrual frequency or experienced 3-11 months of amenorrhoea; and naturally post-menopausal if they reported amenorrhoea for 12 consecutive months or more.
Statistical analysis
To illustrate within-participant transitions of MHT use and transitions of menopause status across the surveys, Sankey plots (Schmidt, 2008) were generated.
The observational cohort as a sequence of non-randomized nested 'trials'
The lack of randomization in observational studies is a major limitation in evaluating the causal effect of treatment exposure on outcomes. To mimic the design of a randomized trial, Hernán et al. (2008) proposed a '(non) randomized trial' design using longitudinal observational data by defining initiators and non-initiators of MHT based on two successive waves. For instance, in the present study, women who, in the 1996 questionnaire, had reported no use of MHT and in the 1998 questionnaire reported use of MHT or no use of MHT were classified as initiators and non-initiators, respectively. Hence, initiators were similar to participants randomized to MHT in a clinical trial, and non-initiators resembled the control group. The initiators group included both first-time users of MHT and re-initiators (i.e. those who had stopped MHT prior to 1996 and were non-users in 1996 but had re-started use in the period between 1996 and 1998). In addition, the present study included a third group: existing users, defined as those who were using MHT in 1998 and in 1996 at the time of the initial questionnaire. This approach was similarly conducted at Wave 2 through to Wave 6, and so five non-randomized 'trials' between 1998 and 2010 were obtained. To increase the efficiency of the estimates, all five trials were pooled in a single analysis.
Women were followed from the start of follow-up to CVD death, death from other causes, loss to follow-up or March 2013, whichever occurred first. Unlike in a clinical trial, the time of therapy initiation, the most appropriate time of start of follow-up for initiators was not known with precision in the ALSWH study, hence this needed to be estimated. In the present study, the start of follow-up for the first 'trial' was estimated as the time the participant returned the 1998 questionnaire. The start of follow-up for the other additional trials was determined similarly. In each trial, we used the corresponding questionnaire information to apply the above criteria at the start of follow-up to define the initiators, non-initiators and existing users.
Competing risk Cox proportional hazards model
To evaluate the risk of MHT in terms of CVD death, the competing risk Cox proportional hazards model was applied (Fine and Gray, 1999 ) (where non-CVD death was the competing risk) whereas risk of overall mortality was estimated using a standard Cox model. The covariates were assessed as potential confounding variables using Greenland's (Greenland, 1989) change-in-estimate (CIE) approach. Confounders, consisting of level of education, age and self-rated health, were identified using a CIE threshold of >5%. Thereafter, multivariable models were adjusted for these three factors. Hazard ratios (HR) for initiators (as well as existing users) compared with non-initiators for CVD death as well as overall mortality were estimated. Since many women participated in more than one of these trials (up to a maximum of five), a robust variance estimate was used to account for within-person correlation.
In subgroup analysis, we tested the interaction between menopause status and MHT use in the Cox model, and further carried out stratified analysis by menopausal status: peri-menopause, hysterectomy/ oophorectomy and post-menopause. Univariable and adjusted analyses (adjusted for age, level of education and self-rated health) were included for comparison.
Results
Transition of hormone therapy
At each wave, the participants were classified as MHT 'user', MHT 'non-user' or 'missing' according to the survey responses. Of 13 715 participants in Wave 1, 2582 (18.8%) were MHT users, 11 099 (80.9%) were MHT non-users and 34 were classified as missing. In the following waves, due to the death, loss to follow-up and withdrawal, the total participants decreased from Wave 2 (1998) to Wave 6 (2010). To show changes in MHT use for participants from 1996 to 2010, a Sankey bar chart is presented in Fig. 1 to show For women with hysterectomy/oophorectomy, PBS data showed that 9% were prescribed progesterone (with or without oestrogen) and the remaining 91% were prescribed oestrogen only. For women with an intact uterus, the proportions were 41 and 59%, respectively. 
Transition of menopause status
The menopausal status of participants at each wave as well as transitions between waves is shown in Fig. 2 . The percentages of each menopause group at each wave for the Sankey plot were calculated based on the number of participants reporting menopause status in all waves. Among those participants with menopause status reported in all six waves, the percentage of participants with hysterectomy/oophorectomy increased steadily over time, from 22% in 1996 to 34% in 2010. At Wave 6, most of the women were classified as either hysterectomy/oophorectomy or post-menopause.
The non-randomized 'trials'
A total of 13 715 participants completed the first survey in 1996. We excluded 951 women who did not provide information on hormone therapy use in any of the trials or joined the survey intermittently without falling into any of the three MHT exposure groups. Thus, 12 764 women met our eligibility criteria for at least one 'trial'. By applying the definition of initiators, non-initiators and existing users, 52 701 nonrandomized trial participants were included across the five trials (individual participants could be included up to 5 times). Of these, 6846
were excluded due to missing menopause status, pre-menopausal status or classification as 'other'. Thus, a total of 45 855 'trial participants' met the eligibility criteria for inclusion in the analysis. A total of 583 participants died of CVD or death from other causes (77 CVD, 97 breast cancer, 277 other cancer and 132 other cause). The remaining participants were either lost to follow-up or were alive at March, 2013. Table I shows the baseline characteristics of initiators, noninitiators and existing users included in the pooled analysis at Trial 1 (baseline data are shown for Trials 2-5 in Table S1 ). Table II shows the number of participants, initiators, CVD deaths and overall deaths per 'trial' as well as the corresponding information in the hysterectomy/oophorectomy, peri-menopause and post-menopause groups.
Estimates of the association between MHT and CVD death and all-cause mortality After adjusting for the confounding variables (Table III) (0.66; 0.35-1.24). For all-cause mortality, however, the risks were reduced for both initiators (0.69; 0.55-0.87) and existing users (0.80; 0.70-0.91) compared with non-initiators of MHT. In the subgroup analysis by menopausal status, women with hysterectomy/oophorectomy had lower risks for CVD mortality in the adjusted model for both initiators (0.14; 0.02-0.98) and existing users (0.55; 0.34-0.90) of MHT compared with non-initiators, whereas no evidence of associations was found for women whose MHT commenced during or after menopause. Similarly for all-cause mortality, only women with hysterectomy/oophorectomy had lower risks for both initiators (0.47; 0.31-0.70) and existing users (0.69; 0.58-0.82) compared with non-initiators of MHT.
Discussion
In a study of >12 000 Australian women aged 47-52 years in 1998 and followed for up to 15 years, 2-15% initiated hormone therapy at each survey wave and 34% had hysterectomy/oophorectomy by 2010. The proportion of women taking hormone therapy reached a peak of 33% in 2001 but then decreased possibly as a result of the large WHI trial reported in 2002 suggesting adverse effects of treatment outweighing benefits. In comparing initiators of hormone therapy with non-initiators, we found a possible protective effect overall for all-cause mortality that appeared to be largely driven by the subgroup of women with hysterectomy/oophorectomy. Analysis of CVD deaths showed a similar effect size overall but failed to reach statistical significance possibly due to a lack of events. Findings were similar for existing users although the protective effects were slightly smaller.
The main finding of our study is consistent with a recent Cochrane review (Boardman et al., 2015) , which reported that women who started hormone therapy within 10 years after menopause had lower mortality and coronary heart disease compared with untreated patients. The Cochrane review reported a 30% reduced risk of allcause mortality for hormone therapy commenced within 10 years of menopause compared with the 31% reduced risk we found overall for initiators and 20% reduced risk for existing users. Our finding in women with hysterectomy/oophorectomy is also largely consistent with subgroup analysis of the WHI trial of women aged 50-59 with prior hysterectomy that showed a protective effect in terms of CVD, myocardial infarction and all-cause mortality (LaCroix et al., 2011; Manson et al., 2013) . However, the size of the protective effect in our study for all-cause mortality is larger than that shown in the WHI trial (risk reduction of 53% for initiators, 31% for existing users versus 27% in the WHI trial). One explanation for the risk reduction in CVD and all-cause mortality evident for women with hysterectomy/oophorectomy is that these women primarily receive the oestrogen only MHT. Bold values indicate statistically significant estimates (P < 0.05).
In contrast, many women with an intact uterus receive the combined oestrogen and progestogen MHT, since progestogen reduces the risk of endometrial cancers, but has also been associated with increased risks of CVD and breast cancer (Rosano et al., 2000; Fenton and Panay, 2015) . However, the reduced risk could also be due to factors or indications for having had a hysterectomy. Our study has a number of strengths but also some limitations. The strengths include the large sample size, follow-up for up to 15 years, prospective study design and complete information on death including cause of death. We used methodology that has been previously shown to provide results consistent with those reported in a randomized study. This is important to minimize bias that is often associated with observational studies. Our results are largely consistent with those reported in the randomized studies of MHT. Limitations include the observational nature of the study, small number of deaths, MHT use being self-reported and classification of menopausal status also based on self-reported information. Consequently, it is possible that there is some misclassification of our main exposure as well as menopausal status; however, we do not believe that the potential misclassification would be sufficient to change the study conclusions.
There are some differences between the method of analysis we used and that implemented by Hernán et al. (2008) . We included women with hysterectomy, women with history of cancer and CVD, and only adjusted for variables that had evidence of a confounding effect on the exposure/outcome association. Hernan et al. excluded women with hysterectomy, previous cancer, acute myocardial infarction and stroke, and adjusted for a large number of covariates without formally considering their status as confounders. We included the existing users in the analysis, although we report all results separately for initiators and existing users. Hernan et al. excluded existing users of MHT for all analyses. We were unable to include covariates on diet, parental history of myocardial infarction, husband's education, cholesterol level and multivitamin and aspirin use.
Conclusion
The main findings from this study, as well as those based on clinical trials, suggest that women considering hormone therapy soon after menopause should be reassured that treatment is unlikely to increase their risk of CVD mortality or all-cause mortality. For women with hysterectomy/oophorectomy, there may even be a protective effect of hormone therapy on all-cause mortality and CVD mortality. It is currently unknown what the optimal duration of treatment is, with the protective effects reported in the Cochrane review based on trials with follow-up ranging from 3.4 to 10 years.
